The endoscopy equipment market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World.

The report "Endoscopy Equipment Market by Product (Endoscope (Flexible, Rigid, Capsule, Robot-assisted, Disposable), Visualization Systems (Video Converters, Recorders, Processors), Other endoscopic, Accessories), Application, End User - Global Forecast to 2027", is projected to reach USD 40.6 billion by 2027 from USD 28.9 billion in 2022, at a CAGR of 7.0%. The growth in this market is driven by Surging requirement for endoscopy to diagnose and treat target diseases, increasing investments, funds, and grants by governments and other organizations worldwide to improve healthcare infrastructure and research areas of endoscopy and Increasing preference for minimally invasive surgeries.

In 2021, North America accounted for the largest market share, followed by Europe and the Asia Pacific. The Asia Pacific market, on the other hand, is projected to register a CAGR during the forecast period. Factors such as the growing number of hospitals, improving healthcare infrastructure, increasing healthcare expenditure, growing patient population, surging demand for minimally invasive surgeries, as well as favorable government policies for single-use endoscopy devices, boost the growth of the endoscopy equipment market in the Asia Pacific.

Europe Endoscopy Equipment Market

Europe accounted for the second-largest share of the endoscopy equipment market in 2021.

Major factors driving the growth of the endoscopy equipment market in Europe include the rising investments by governments, increasing availability of funds to support medical innovations in the UK, the rising incidence of cancer in the UK, and the significant presence of key players in Germany.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689

Endoscopy Equipment Market - GERMANY

Germany to account for largest share of European market during forecast period.

Germany’s large share can be attributed to its robust healthcare spending compared to other European regions. According to Statistisches Bundesamt (Destatis), in 2020, health expenditure in Germany amounted to EUR 440.6 billion; the total health expenditure rose by EUR 26.8 billion or 6.5% compared with 2019. Healthcare in Germany is funded by a statutory contribution system, which ensures free care through health insurance funds. Also, Statutory Health Insurance is mandatory for all individuals who earn less than USD 62,244 (EUR 56,250) per year. Insurance payments are based on the income of the individual. As a result of the favorable insurance system, expensive procedures are reimbursed, which considerably reduces the burden on patients, allowing them to opt for the most effective treatments. The favorable reimbursement scenario in the country will lead to the recommendation of endoscopy surgeries, which, in turn, will augment the demand for endoscopy devices.

The rise in the aging population in Germany is leading to an increasing number of patients suffering from chronic diseases. The rising incidence of cancer is further adding to the burden on the healthcare system, resulting in an increasing demand for technological innovations and minimally invasive surgical procedures, new skills, and new responsibilities in the health workforce. In 2020, Germany reported 538,140 people who had cancer (Source: World Cancer Research Fund International, WCRF), and it is estimated that around 289,396 men and 248,744 women in the country developed cancer in 2020. Many cancers have a high chance of being cured if detected early and treated adequately, but many patients are diagnosed in late or advanced stages. It is, therefore, important to improve cancer diagnostic methods in early or even pre-syndrome stages, which highlights the need for diagnostic technologies such as endoscopy.

Additionally, various organizations such as Deutsche Forschung Gemeinschaft/German Research Foundation (DFG), German Cancer Research Center (DKFZ), German Cancer Aid, Helmholtz-Association, and Max-Planck-Gesellschaft/Max Planck Society (MPG) are funding research projects for the development of technologies and therapies for the prevention and treatment of cancer.

Germany is home to some major endoscopy equipment manufacturers, such as KARL STORZ, Richard Wolf GmbH, Maxer Medizintechnik GmbH, Xion GmbH, and Tekno-Medical Optik-Chirurgie GmbH. These players ensure the continuous supply of products, including the launch of new and innovative products, in the region. The significant number of endoscopy equipment manufacturers, along with continuous research pertaining to technical advancement in the country, signifies the strong potential for the endoscopy equipment market in Germany.

Endoscopy Equipment Market - FRANCE

High-quality healthcare system to offer coverage to all citizens

Over the years, France has introduced various regulations and initiatives to improve its healthcare infrastructure. France invests around 11.1% of its GDP in healthcare, which is the second highest amongst EU countries (Source: OECD). This has aided the growth of the healthcare sector in the country.

In 2018, health expenditure per capita in France was USD 4,690. The healthcare system in the country is largely financed by the government's national health insurance. According to the WHO, France’s healthcare services are ranked among the best in the world. Its significant share in the global endoscopy equipment market can be attributed to the presence of a significantly large base of the aging population. According to the US Census Bureau, in 2020, the total population of France was 65.3 million, with around 21% of the population aged 65 years and above. This figure is expected to reach nearly 23.4% by 2030. The rapid growth in the aging population is leading to high demand for age-related surgical treatments in the country, which is further driving the growth of the market of endoscopy equipment. Additionally, cancer prevalence and therapeutic surgeries are on the rise in France, which is expected to play a key role in the growth of the endoscopy equipment market in the country.

Moreover, France’s government uses a statutory health insurance system (SHI), which is mandatory for all individuals. Under the SHI, a major amount is financed by the employer and employee payroll taxes. The cost of insurance for non-eligible citizens, such as long-term unemployed citizens, is covered by the state. This favorable insurance system in France reduces the healthcare cost spent by patients, which is expected to drive the adoption of advanced and effective minimally invasive treatments in the country.

Endoscopy Equipment Market - UK

Investments by hospitals in new and advanced endoscopy equipment to propel market

The demand for minimally invasive surgeries such as endoscopy in the UK has increased due to the growing aging population, the rising cases of cancer, as well as the implementation of the National Bowel Cancer Screening Program by the National Health Survey. According to Cancer Research UK, there are more than 367,000 new cancer cases in the UK every year. Each year, more than one-third (36%) of all cancer cases in the UK are diagnosed with the elderly population (above 75 years). Treating cancer through minimally invasive surgeries in an elderly patient offers various advantages, such as minimal postoperative complications and faster recovery compared to open surgeries. The incidence rates for all cancers combined are projected to rise by 2% in the UK between 2014 and 2035.

These factors have spurred investments in new endoscopy equipment or the expansion of existing endoscopy units by many UK hospitals. Some recent investments by hospitals are as follows:

· In May 2021, The United Lincolnshire Hospitals NHS Trust, UK, invested GBP 1.4 million to improve patients’ access to diagnostic imaging techniques, such as endoscopy.

· In July 2020, the Scottish government funded GBP 1.35 million to Raigmore Hospital Inverness, UK, to allow NHS Highland to place a temporary unit dedicated solely to endoscopy services and pay for additional staff to carry out the work.

· In December 2018, Norfolk and Norwich University Hospital (NNUH, UK) moved its gastroenterology department to the Quadram Institute and expanded its endoscopy services.

As UK hospitals continue to invest in purchasing new endoscopy equipment, the market in this country is expected to grow during the forecast period. Governmental initiatives for developing innovative and minimally invasive techniques for the diagnosis of cancer will accelerate the growth of the endoscopy equipment market in the UK

Endoscopy Equipment Market - ITALY

Receptivity of high-quality and technologically advanced diagnostic and therapeutic equipment to foster market

Italy is a mature market for medical equipment, and its high per capita income and sophisticated healthcare system translate into demand for a broad range of cutting-edge medical equipment. Italy is the fourth-largest market for medical equipment and supplies in Europe after Germany, France, and the UK, with about 3,957 companies (including 42% distributors, 53% producers, and 5% service providers) and a workforce of 76,400. The COVID-19 pandemic has negatively affected the medical devices market in Italy.

According to the International Trade Administration, public hospitals account for over 75% of medical device sales, with the remaining 25% of sales to the private sector. Despite having a considerable local manufacturing industry, the domestic market for medical equipment is highly dependent on imports. Major suppliers are from the Netherlands, Germany, Belgium, France, and the US, which had a 5.4% share of Italian imports, estimated at USD 6,503 million in 2021. Major US medical device imports to Italy include diagnostic imaging, dental, and patient aids. At the beginning of 2020, the Italian government allocated EUR 235 million to purchase basic diagnostic devices as a part of the Italian healthcare plan to improve local assistance to patients and therefore reduce dependence on emergency rooms. The Italian market is receptive to high-quality and technologically advanced diagnostic and therapeutic equipment and products, such as endoscopes.

Endoscopy Equipment Market - SPAIN

Prevalence of cardiovascular diseases to stimulate market

According to the Spanish Ministry of Health, Consumer Affairs and Social Services, total (public and private) healthcare expenditure in Spain in 2019 was USD 117.5 billion, representing 9% of the country’s GDP. The average per capita expenditure (public and private) was USD 2,524 (USD 1,904 –public, USD 741 – private). Each of the 17 regional governments administers its respective healthcare budget authorized by the central government. Spain’s healthcare spending will reach over 10.83 billion Euros between 2018 and 2030.

According to an article published by Héctor Bueno, Beatriz Pérez-Gómez in the journal Circulation, 2019 edition, cardiovascular disease is the number one cause of death in Spain, leading to 120,000 deaths every year. According to IS Global research, ischemic heart disease was the leading cause of death in Spain in 2018, accounting for 14.6% of all deaths. Thus, with the rising prevalence of cardiac diseases and the use of endoscopy in several surgeries, such as coronary artery bypass surgery, left ventricular cardio-endoscopic surgery, and aortic valve replacement, the Spanish market is expected to grow during the forecast period.

Endoscopy Equipment Market - REST OF EUROPE

The market in Rest of Europe is primarily studied for Russia, Finland, Sweden, Switzerland, Turkey, the Czech Republic, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Austria, and Belgium.

According to the US Census Bureau, Greece, Portugal, Finland, Bulgaria, Sweden, and Denmark had high percentages of the aging population (to the total population), contributing to the prevalence of age-related disorders in these countries in the coming years.

Factors such as the increasing investments for the improvement and expansion of healthcare infrastructure in several Rest of European countries are driving the growth of the endoscopy equipment market in Rest of Europe. A number of initiatives have been taken to expand and improve healthcare infrastructure in the region. For example, in Russia, the government develops and uses innovative medical equipment with the rising need for replacing outdated devices and the limited supply of new devices. Such initiatives are expected to aid the growth of the overall endoscopy equipment market in Russia.

The pricing of endoscopic devices and accessories is a key factor across all European countries. Taking into consideration the global economic crisis and competitive intensity prevailing in the European market, endoscopy device manufacturers are being pressured to lower their prices and offer discounted product bundles to win tendered contracts from cost-constrained hospitals. In countries such as Italy and Spain, price competition is a primary factor restricting revenue growth. In addition, brand loyalty is an important factor in Europe; global players need to build strong customer relations to establish themselves in the region.

A number of premium-priced products—particularly in the video endoscopes and endoscopic retrograde cholangiopancreatography devices markets, which often include technological improvements—will be increasingly adopted as these devices positively affect overall patient care as well as the quality of life and, in certain cases, can even reduce overall healthcare costs. Further, there has been a shift from reusable to disposable devices, which will fuel market growth because disposable devices are associated with higher per-procedure costs. This shift will be driven by concerns over the need for proper device sterilization and the desire to eliminate the risk of infections and potential sample contamination during biopsies.

Although the European market is flooded with cheaper Asian imports, most European companies do not view these imports as major threats owing to their relatively poor quality. Aftersales services and product quality are two important parameters that European customers look for. Successful and well-established endoscope-providing companies offer a wide range of aftersales services to customers, including instrument repair and replacement, instrument loans, maintenance contracts, training, and technical support.

Full Article Read: https://www.marketsandmarkets.com/Market-Reports/endoscopy-devices-market-689.html

The single-use bioprocessing market is divided into five major regions—North America, Europe, Asia Pacific, Latin America (LATAM), and the Middle East and Africa (MEA).

The report "Single use Bioprocessing Market Size, Growth by Product (Media Bags and containers, Bioreactors, Mixers, Assemblies), Application (Cell Culture, Mixing, Storage, Filtration, Purification), End User (Biopharma Companies, CROs, CMOs) - Global Forecast 2026", is projected to reach USD 20.8 billion by 2026, at a CAGR of 20.5%.

The rising demand for biopharmaceuticals and advantages of single-use bioprocessing (such as high energy efficiency, low water usage, less floor space requirement, reduced installation cost, decreased risk of product cross-contamination, and fast implementation) drive the adoption of the single-use bioprocessing market. On the other hand, the high disposable cost and issues related to the transfer of leachable and extractables into the solvent, which can cause contamination, are the major factors restraining the growth of this market.

Emerging markets such as China, India, Japan, and Brazil are expected to present significant growth opportunities for the major stakeholders in this market. The market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The growth in this region can be attributed to the expanding biomanufacturing sector, increasing government support, developing R&D infrastructure, and growing outsourcing to this region from North America and Europe.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297

Single use Bioprocessing Market - Europe

Around 9.9% of the European gross domestic product (GDP) was spent on healthcare in 2018. (Source: Eurostat). According to PhRMA, medicines deriving from biotech innovations (biopharmaceuticals) account for ~20% of all marketed medicines and represent around 50% of all new medicines in the pipeline. Increasing government support in terms of setting guidelines and rules for the development and pre-marketing, and commercialization approval of biosimilars is a major factor driving the growth of the European biopharmaceuticals market. Owing to this, players in the biopharmaceutical market are expected to increase focus on the R&D of innovative biologics, thereby increasing the demand for economic and suitable techniques and equipment for R&D. Single-use bioprocessing systems help in reducing initial investments and are suitable for R&D; these advantages are driving their higher uptake.

Development and manufacturing costs of biologics are generally higher than those of nonbiologics. Due to the economic downturn in the region, this is expected to be one of the major factors restraining the growth of the biologics market in Europe. However, several European countries have launched new funding initiatives to ensure that the national biotechnology sectors are better positioned.

Single use Bioprocessing Market - GERMANY

Increasing adoption of single-use bioprocessing equipment by biopharma and CDMO companies to drive the market growth

Germany is a mature market with a large pharmaceutical production capacity and high healthcare expenditure. Many companies are expanding their biomanufacturing facilities to fulfill the growing demand for biologics. For instance, in 2021, Richter Helm Biologics GmbH expanded its biological manufacturing facility in Bovenau, Germany.

As bioprocess optimization is the key focus of CDMOs to maintain cost-efficiency, the adoption of single-use bioreactors is increasing as they offer increased flexibility and improved productivity & efficiency. For instance, in 2021, Eppendorf expanded production capacity at the Oldenburg in Holstein site in Germany to produce laboratory consumables made of high-quality plastic such as pipette tips and tubes, microtiter plates, and single-use bioreactor vessels. Such developments are expected to drive the growth of the single-use bioprocessing market in Germany.

Single use Bioprocessing Market - UK

Increasing healthcare expenditure is driving the growth of the ventilators market in the country

The growth of the biopharmaceuticals market in the UK is one of the major factors driving the demand for single-use bioprocessing in this region. The key growth drivers for the biopharmaceutical market in the UK are well-established innovation centers for biotechnology (such as the Centre for Process Innovation) and rising government support for an increasing number of biotech clusters in the region. According to the UK BioIndustry Association Report; Life sciences: Catalysing Investment and Growth, in 2018, UK biotech companies raised a funding of USD 2.3 billion (£2.2 billion) of private investment, almost double the amount raised in the previous year and more than 20 times the USD 108 million (£100 million) invested by Innovate UK grant funding in 2017/18 from the previous year. The sector continued this trajectory in the first quarter of 2019, raised USD 197 million (£182 million), almost USD 54 million (£50 million) more than during the same period a year earlier, suggesting the sector could break the fundraising record set in 2018. An increase in funding will boost the biotech industry to adopt advanced technologies for effective biomanufacturing solutions (such as single-use products including media bags, connectors, and bioreactors) to speed up the development of new molecules and increase production efficiency. Thus, an increase in funding for drug development is expected to propel the demand for single-use bioprocessing equipment in the UK.

Single use Bioprocessing Market - FRANCE

Increasing investments in life sciences R&D infrastructure development to drive the market growth in France

France has 720 biotech companies and 160 MedTech companies, employing more than 50,000 people. It has the third-largest number of biotech companies in Europe, after Germany and the UK. (Source: BiotechGate; La French Health Tech, 2017).

Increasing private and public funding for biotech research is fueling the growth of the biopharmaceutical market in the country, which in turn drives the demand for single-use technologies, including bioreactors, bags, and containers for efficient bioprocessing.

Single use Bioprocessing Market - REST OF EUROPE

The Rest of Europe (RoE) comprises Italy, Spain, the Netherlands, Switzerland, Sweden, Belgium, Turkey, and the Czech Republic. Among these, Italy and Spain are the major markets for single-use bioreactors and other bioprocessing equipment due to well-established life science research sectors and the pharmaceutical industry in these countries.

The life science research sector in Italy is the third-largest in Europe, after Germany and France. According to an article published in PharmaVOICE (2019), there are 67 life science projects in the discovery phase in Italy. Around half (45%) of the projects are on biotech products [such as monoclonal antibodies (26%), recombinant proteins (10%), and products for cell therapy (3%), gene therapy (4%), and regenerative medicine (2%)]. Similarly, around 700 biotechnology companies are operating in Spain currently. The strong product pipeline and large manufacturing footprint in these countries are factors expected to increase the demand and uptake of single-use bioprocessing products in biomanufacturing processes, thereby driving market growth in this region.

Single use Bioprocessing Market - TOC:

EUROPE

· TABLE 136 EUROPE: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)

· 9.3.1 GERMANY

o 9.3.1.1 Increasing adoption of single-use bioprocessing equipment by biopharma and CDMO companies to drive the market growth

§ TABLE 144 GERMANY: MARKET, BY PRODUCT, 2017–2020 (USD MILLION)

§ TABLE 145 GERMANY: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)

§ TABLE 146 GERMANY: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)

§ TABLE 147 GERMANY: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)

§ TABLE 148 GERMANY: MARKET, BY END USER, 2017–2020 (USD MILLION)

§ TABLE 149 GERMANY: MARKET, BY END USER, 2021–2026 (USD MILLION)

· 9.3.2 UK

o 9.3.2.1 Rising government support for biotech companies to propel the demand for advanced technologies in the UK

§ TABLE 150 UK: SINGLE USE BIOPROCESSING MARKET, BY PRODUCT, 2017–2020 (USD MILLION)

§ TABLE 151 UK: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)

§ TABLE 152 UK: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)

§ TABLE 153 UK: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)

§ TABLE 154 UK: MARKET, BY END USER, 2017–2020 (USD MILLION)

§ TABLE 155 UK: MARKET, BY END USER, 2021–2026 (USD MILLION)

· 9.3.3 FRANCE

o 9.3.3.1 Increasing investments in life sciences R&D infrastructure development to drive the market growth in France

§ TABLE 156 FRANCE: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2017–2020 (USD MILLION

§ TABLE 157 FRANCE: MARKET, BY PRODUCT, 2021–2026 (USD MILLION)

§ TABLE 158 FRANCE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)

§ TABLE 159 FRANCE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)

§ TABLE 160 FRANCE: MARKET, BY END USER, 2017–2020 (USD MILLION)

§ TABLE 161 FRANCE: MARKET, BY END USER, 2021–2026 (USD MILLION)

· 9.3.4 REST OF EUROPE (ROE)

o TABLE 162 ROE: MARKET, BY PRODUCT, 2017–2020 (USD MILLION)

o TABLE 163 ROE: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)

o TABLE 164 ROE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)

o TABLE 165 ROE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)

o TABLE 166 ROE: MARKET, BY END USER, 2017–2020 (USD MILLION)

o TABLE 167 ROE: MARKET, BY END USER, 2021–2026 (USD MILLION)

Read Full Details of Research Study: https://www.marketsandmarkets.com/Market-Reports/single-use-bioprocessing-market-231651297.html

According to a new report added on MarketsandMarkets™, the Global Enteral Feeding Formulas Market is projected to reach USD 8.2 billion by 2027 from USD 5.2 billion in 2022, growing at a CAGR of 9.5%. The research report studies the market landscape and its growth prospects during the forecast period. Several research tools such as Porter’s five forces analysis, SWOT analysis, and so on, have been exercised to provide a precise understanding of the overall market. The market research report provides an in-depth analysis of the major trends and technologies that are playing an important role in the growth of the market over the coming years. The study provides a detailed assessment of Global Enteral Feeding Formulas Market, in terms of revenue, throughout the aforementioned period.

Browse 233 market data Tables and 46 Figures spread through 233 Pages and in-depth TOC on "Enteral Feeding Formulas Market by Product (Polymeric, Elemental, Disease-specific), Stage (Adults, Pediatrics), Application (Oncology, Gastroenterology, Neurology, Hypermetabolism), End User (Hospitals, LTCF, Home care) - Global Forecast to 2027".

Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74876393

The research report provides a detailed analysis of the current and historical market trends, development patterns, and the correlations between the market dynamics and forecasts, as well as the hard-hitting market facts. The global Enteral Feeding Formulas Market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights. The report also takes into account the market drivers, restraints, challenges, threats, and the potential growth opportunities influencing the growth pattern of the key market segments. The section also focuses on the key micro- and macroeconomic factors impacting the growth of the overall market.

Prominent Players:

Major player included are Abbott (US), Nestlé S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi (Germany), B. Braun Melsungen AG (Germany), Otsuka Holding Co. Ltd. (Japan), Nutritional Medicinals, LLC (US), Kate Farms (US), Medtrition Inc. (US), Victus, Inc. (US), Global Health Products, Inc. (US), Meiji Holdings Co., Ltd. (Japan), Reckitt Benckiser Group PLC. (UK), Hormel Foods Corporation (US), DermaRite Industries, LLC. (US), Medline Industries, LP. (US), Real Food Blends (US), and Ajinomoto Cambrooke, Inc. (US).

Abbott is the leading player in the enteral feeding formulas market. The company operates in the market through its Nutritional Products segment. With its strong global presence and wide distribution network, the company possesses a robust product portfolio comprising adult and pediatric nutritional formulas. The company focuses on developing innovative formulas and expanding its global presence.

Nestlé is a multinational health, nutrition, and wellness company. It manufactures and markets milk-based products, pharmaceuticals, baby foods and cereals, ophthalmic goods, and cooking aids. The company operates in seven major business segments—Powdered and Liquid Beverages, Petcare, Nutrition and Health Science, Prepared Dishes and Cooking Aids, Milk Products and Ice cream, Confectionary, and Water. The company provides a range of enteral feeding formulas through its Nestlé Health Science segment. In 2021, the Nestlé Health Science segment contributed the largest share of 5.5% to the company’s revenue, which was 3.9% in 2020. The continuous growth of this segment is primarily due to its strong product portfolio, brand recognition, and high demand for nutritional formulas. In 2021 and 2022, the company acquired Orgain (US) and The Bountiful Company (US), which enabled the company to expand its presence in the market. The company operates in over 186 countries across Zone EMENA (Europe, Middle East, and North Africa), Zone AMS (The Americas), and Zone AOA (Asia, Oceania, and Africa).

Fresenius Kabi has a strong global footprint and focuses on providing high-quality, innovative clinical nutrition solutions. The company has a wide geographic presence in established markets and a broad product portfolio that includes nutritional supplements and tube feed & pediatric feed products. Along with this, Fresenius Kabi supports external development projects. The company also established the United for Clinical Nutrition (UFCN) initiative to raise awareness of disease-related malnutrition worldwide. This has enabled the company to expand its geographic presence.

Danone observed increased demand for its specialized nutrition formulas in the Asia Pacific. Infant nutrition posted growth in revenue, driven by China and the Rest of the World. The company also focuses on adopting collaboration and geographic expansion to sustain its position in the market. With the recall of some nutritional formulas by Abbott in May 2022, Danone announced that it would double the shipments of Neocate formula to the US.

The company has a strong foothold in the enteral feeding formulas market. This is due to its strong sales and distribution network. The company offers a wide range of child and adult feeding formulas in the market through its Specialized Nutrition business segment. The specialized nutrition business of Danone is expected to grow through multi-channel sales strategies and the expansion of its product portfolio.

B. Braun Melsungen AG focuses on expanding its enteral feeding product portfolio. For enteral nutrition, the company offers feeding formulas and devices such as standard diets, specific diets, enteral nutrition pumps, pump administration systems, gravity administration systems, feeding tubes, and safety systems. A product portfolio enables the company to maintain its competitive position in the market. In 2021, the Healthcare business witnessed a 5.1% in revenue, with growth in North America, Germany, and Latin America markets being the major drivers, followed by Switzerland and East Europe. Additionally, Japan, Australia, and Thailand exhibited double-digit growth. The company aims to establish its market position in these countries, driven by increasing demand for enteral nutrition.

This report categorizes the Enteral Feeding Formulas Market to forecast revenue and analyze trends in each of the following submarkets:

By Product

· Standard Formula

· Disease specific

· Diabetic Formula

· Renal Formula

· Hepatic Formula

· Pulmonary Formula

· Other Disease Specific Formula

· Peptide based formula

· Other Formula

By Stage

· Adults

· Pediatric

By End User

· Hospitals

· Long Term Care facilities

· Nursing Homes

· Assisted Living Facilities

· Home Care Agencies & Hospices

By Application

· Oncology

· Gastrointestinal Diseases

· Neurological Disorders

· Diabetes

· Other Applications

By Region

· North America

o US

o Canada

· Europe

o UK

o Germany

o France

o Italy

o Spain

o Rest of Europe

· Asia Pacific

o Japan

o China

o India

o Rest of APAC

· Latin America

· Middle East & Africa

Enteral Feeding Formulas Market Key questions answered in the report include:

1. What will be the enteral feeding formulas market size and the growth rate by the end of the forecast period?

2. What are the key factors driving the growth of the global enteral feeding formulas Market?

3. What are the key market trends impacting the growth of the market?

4. What are the challenges to enteral feeding formulas market growth?

5. Who are the leading competitors operating in the global enteral feeding formulas market?

6. What are the potential growth opportunities and threats faced by the leading competitors in the market?

7. What are the key outcomes of Porter's five forces analysis and the SWOT analysis of the key players functioning in the global enteral feeding formulas market?

Recent Developments:

· In February 2022, Nestlé (Switzerland) agreed to purchase a majority stake in Orgain, a leader in plant-based nutrition. This acquisition would complement Nestlé Health Science’s existing portfolio of nutrition products.

· In September 2021, Abbott (US) launched plant-based proteins and organic food ingredient enteral formulas for tube feeding.

Content Source:

https://www.marketsandmarkets.com/PressReleases/enteral-feeding-formulas.asp

https://www.marketsandmarkets.com/ResearchInsight/enteral-feeding-formulas-market.asp

https://www.prnewswire.com/news-releases/enteral-feeding-formulas-market-worth-8-2-billion-by-2027--exclusive-report-by-marketsandmarkets-301603255.html

MarketsandMarkets™ has added a new report titled, ‘Global Single use Bioprocessing Market’ in its vast database of research reports. The Global Single-use Bioprocessing Market is thoroughly analyzed in this report, providing valuable insights into its current landscape and future growth prospects. The report covers the forecast period of 2021 to 2026 and offers a comprehensive overview of the market by utilizing a meticulous approach that involves studying, synthesizing, and consolidating data from multiple reliable sources. With the aim of accurately determining the market size, the report presents a detailed analysis of key factors and trends driving the growth of the single-use bioprocessing market. The findings of this report serve as a valuable resource for industry stakeholders, researchers, and decision-makers seeking to understand the dynamics of the global single-use bioprocessing market and make informed business decisions.

The report is helpful to everyone, right from an expert, professional, analyst, employee to a manager. This report contains statistical data that enables the reader to have a detailed summary and the overall insights, which can be applied in the decision-making process, taking into consideration the core and crucial business areas. The report also contains some illustrations and presentations, in the form of charts, graphs, and tables, along with qualitative and quantitative data, so as to understand and gain insights. The report also helps the readers by availing the ready-to-access analytical data provided by the industry experts.

Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297

The report "Single use Bioprocessing Market Size, Growth by Product (Media Bags and containers, Bioreactors, Mixers, Assemblies), Application (Cell Culture, Mixing, Storage, Filtration, Purification), End User (Biopharma Companies, CROs, CMOs) - Global Forecast 2026", is projected to reach USD 20.8 billion by 2026, at a CAGR of 20.5%.

The single-use bioprocessing market is highly consolidated with majority of the market share taken up by key players such as Thermo Fisher Scientific (US), Danaher Corporation (US), Sartorius Stedim Biotech S.A. (France), and Merck KGaA (Germany). The key players in this market are increasingly focusing on strategic expansions, partnerships, and product approvals to expand their manufacturing capabilities and increase market presence.

This study categorizes the global single use bioprocessing market to forecast revenue and analyze trends in each of the following submarkets:

By Product

· Single-use media bags and containers

· Single-use assemblies

· Single-use bioreactors

· Disposable mixers

· Other products

By Application

· Filtration

· Storage

· Cell culture

· Mixing

· Purification

By End user

· Biopharmaceutical & Pharmaceutical companies

· Contract Research Organizations and contract manufacturing organizations (CROs & CMOs)

· Academic & Research institutes

Some of the key geographies mentioned in this report include:

· North America (U.S and Canada and rest of North America)

· Europe (Germany, France, Italy and Rest of Europe)

· Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)

· LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Hypothetic Challenges of Single use Bioprocessing Market in Near Future:

· Regulatory Challenges: As the use of single-use bioprocessing technologies becomes more widespread, regulatory bodies may need to develop new guidelines and standards for their use. This could create uncertainty and delay in the adoption of these technologies.

· Supply Chain Disruptions: The COVID-19 pandemic has highlighted the fragility of global supply chains. If there are disruptions in the supply of raw materials or components needed for single-use bioprocessing systems, this could lead to delays and increased costs for manufacturers.

· Environmental Concerns: While single-use bioprocessing systems offer several advantages over traditional stainless-steel systems, they also generate more waste. There may be increasing pressure from regulators and consumers to reduce waste and increase sustainability in the biopharmaceutical industry.

· Cost: While single-use bioprocessing systems offer several advantages, they can be more expensive than traditional stainless-steel systems. This may limit their adoption in certain markets or by smaller biopharmaceutical companies.

· Technology Limitations: While single-use bioprocessing systems have advanced significantly in recent years, there may still be limitations in their performance and scalability for certain applications. This could limit their adoption in certain markets or by certain biopharmaceutical companies.

Top 3 Use Cases of Single use Bioprocessing Market:

· Cell Culture: Single-use bioreactors and other disposable technologies are widely used in cell culture for the production of biologics, such as monoclonal antibodies and recombinant proteins. These systems offer several advantages over traditional stainless-steel systems, including reduced cleaning and validation time, increased flexibility, and reduced risk of cross-contamination.

· Downstream Processing: Single-use chromatography systems and other disposable technologies are used in downstream processing to purify and concentrate biologic products. These systems offer several advantages over traditional stainless-steel systems, including reduced cleaning and validation time, increased flexibility, and reduced risk of cross-contamination.

· Vaccine Production: Single-use bioprocessing technologies are increasingly being used for the production of vaccines. These technologies offer several advantages over traditional stainless-steel systems, including reduced cleaning and validation time, increased flexibility, and reduced risk of cross-contamination. Additionally, single-use bioprocessing systems are well-suited for the rapid production of vaccines in response to outbreaks or pandemics.

Recent Developments:

· In March 2020, Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The business is called Cytiva and is a standalone operating company within Danaher's Life Sciences segment.

· In September 2020, Thermo Fisher Scientific invested more than USD 475 million in new capabilities at its St. Louis site to expand biologics development and manufacturing, cell and gene therapy capabilities, and drug product development capabilities.

Content Source:

https://www.marketsandmarkets.com/PressReleases/single-use-bioprocessing.asp

https://www.marketsandmarkets.com/ResearchInsight/single-use-bioprocessing-market.asp

https://www.prnewswire.com/news-releases/single-use-bioprocessing-market-worth-20-8-billion-by-2026--exclusive-report-by-marketsandmarkets-301350123.html

https://www.globenewswire.com/en/news-release/2023/05/05/2662516/0/en/Single-use-Bioprocessing-Market-is-Expected-to-Reach-20-8-billion-MarketsandMarkets.html

Related Reports:

Single Use Bioreactors Market

Pharmaceutical Filtration Market

Single Use Assemblies Market

Immunotherapy Drugs Market

Chromatography Instruments Market

MarketsandMarkets™ has added a new report titled, ‘Global Medical Electrodes Market’ in its vast database of research reports. The Global Medical Electrodes Market is comprehensively assessed in this report, providing insights into its current landscape and future growth prospects for the forecast period of 2021-2026. The report presents a detailed analysis of the market by employing a rigorous methodology that involves studying, synthesizing, and aggregating data from multiple reliable sources. By presenting a comprehensive scenario of the market, the report accurately calculates the market size and offers valuable insights into key trends and factors driving the growth of the medical electrodes market. This report serves as a valuable resource for industry stakeholders, researchers, and decision-makers seeking to understand the dynamics of the global medical electrodes market and make informed business decisions.

This report caters to a wide range of readers, including experts, professionals, analysts, employees, and managers, providing them with valuable insights and statistical data. With a comprehensive summary and in-depth analysis, the report serves as a crucial tool in the decision-making process, particularly for key business areas. The inclusion of visually appealing illustrations such as charts, graphs, and tables, along with qualitative and quantitative data, facilitates a better understanding of the information presented. By offering ready-to-access analytical data from industry experts, the report empowers readers with the knowledge and insights necessary to make informed decisions.

Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171260948

The report "Medical Electrodes Market Size, Growth by Product [Diagnostic Electrodes (ECG, EEG, EMG), Therapeutic Electrodes (Defibrillator, Pacemaker)], Technology (Wet, Dry, Needle), Application (Neurophysiology, IOM), Usage (Disposable, Reusable), - Global Forecast to 2026 is projected to reach USD 2.1 billion by 2026, at a CAGR of 4.3%.

The global medical electrodes market is fragmented. The prominent players operating in this market include Medtronic (Ireland), Ambu A/S (Denmark), 3M (US), Natus Medical Incorporated (US), Koninklijke Philips N.V. (Netherlands), B. Braun Melsungen AG (Germany), ZOLL Medical Corporation (US), Cardinal Health (US), CONMED Corporation (US), Nihon Kohden Corporation (Japan), Rhythmlink International, LLC (US), Cognionics, Inc. (US), GE Healthcare (US), Compumedics Limited (Australia), and Nissha Medical Technologies (Japan).

This report categorizes the global medical electrodes market into the following segments and sub-segments:

By Product

· Diagnostic Medical Electrodes

o Electrocardiography (ECG) Electrodes

o Electroencephalography (EEG) Electrodes

o Electromyography (EMG) Electrodes

o Other Diagnostic Electrodes [electroretinography (ERG) electrodes and electrooculography (EOG) electrodes]

· Therapeutic Medical Electrodes

o Defibrillator Electrodes

o Pacemaker Electrodes

o TENS Electrodes

o Electrosurgical Electrodes

o Neuromuscular Stimulation Electrodes (NMES)

o Other Therapeutic Electrodes (wound healing electrodes, blood gas electrodes, and iontophoresis electrodes)

By Technology

· Wet Electrodes

· Dry Electrodes

· Needle Electrodes

By Usability

· Disposable Medical Electrodes

· Reusable Medical Electrodes

By Application

· Cardiology

· Neurophysiology

· Sleep Disorders

· Intraoperative Monitoring (IOM)

· Surgical Applications

· Other Applications (vision disorders and wound healing)

Some of the key geographies mentioned in this report include:

· North America (U.S and Canada and rest of North America)

· Europe (Germany, France, Italy and Rest of Europe)

· Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)

· LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Recent Developments:

· In 2021, Sticky Pad Surface Electrodes manufacturered by Rhythmlink International, LLC (US) received FDA clearance for MR Conditional for 1.5 and 3 Tesla MRI environments and now can be used safely and effectively in imaging environments.

· In 2020, Natus Medical, Inc. (US) entered into a partnership with Holberg EEG AS (Norway). This partnership aims to improve and automate the diagnosis of epilepsy by developing and distributing an AutoSCORE algorithm worldwide.

· In 2019, Medtronic (Ireland) entered into a distribution agreement with Alpha Omega (Israel). This agreement aimed to market Medtronic’s surgical navigation products designed for procedures in the brain.

Content Source:

https://www.marketsandmarkets.com/PressReleases/medical-electrode.asp

https://www.marketsandmarkets.com/ResearchInsight/medical-electrode-market.asp

https://www.prnewswire.com/news-releases/medical-electrodes-market-worth-2-1-billion-by-2026--exclusive-report-by-marketsandmarkets-301302818.html

The market research report on the Global Epilepsy Monitoring Devices Marketpresents an in-depth information about the various aspects of the market, on both global and regional scales, which provides a better understanding of the present market landscape. The growth of the Epilepsy Monitoring Devices market has been driven by the soaring demand for Epilepsy Monitoring Devices in the well-established and emerging regions, current technological advancements, and the growing infiltration of the end-use industries.

The report "Epilepsy Monitoring Devices Market by Product (Conventional & Wearable Devices, Standard EEG, Video EEG, Ambulatory EEG, EMG, MEG, Deep Brain Stimulation Devices) End User (Hospitals, Neurology Centres, ASC, Home Care Settings) - Global Forecast to 2026" The global epilepsy monitoring devices market is projected to reach USD 615 million by 2026 from USD 489 million in 2021, at a CAGR of 4.7% during the forecast period. The growth of this market is majorly attributed to the increasing incidence and prevalence of epilepsy, growing preference for ambulatory healthcare and increasing use of wearables, growing demand for continuous monitoring, and the rising awareness of neurodegenerative diseases, including epilepsy. On the other hand, the high cost of complex epilepsy monitoring procedures and devices and the unfavorable reimbursement policies are restraining the growth of this market.

Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62758189

The report presents some illustrations and presentations with regard to the market, which includes graphs, tables and pie charts, representing the percentage split of the strategies adopted by the key players in the global market. The product launches are regarded as one of the key strategies adopted by the leading market competitors in the Global Epilepsy Monitoring Devices Market so as to present novel and innovative products in different business segments.

Natus Medical, Inc. (US), Compumedics Limited (Australia), The Magstim Co. Ltd. (UK), Nihon Kohden Corporation (Japan), and Masimo Corporation (US) were the top players in the epilepsy monitoring devices market during the forecast period. Other major players in the market include Empatica, Inc. (US), Medtronic Plc (Ireland), Boston Scientific Corporation (US), Drägerwerk AG & Co. KGaA (Germany), mjn Neuroserveis S.L. (Spain), Abbott Laboratories, Inc. (US), LivAssured B.V. (Netherlands), BioSerenity (France), Aleva Neurotherapeutics (Switzerland), Medpage, Ltd. (UK), Neurosoft (Russia).

The research report categorizes the Epilepsy monitoring devices market into the following segments and subsegments:

By Product

· Wearable Devices

· Conventional Devices

o Deep Brain Stimulation Devices

o Monitoring Devices

§ EEG Devices

· Standard EEG

· Video EEG

· Others/Ambulatory EEG

§ EMG Devices

§ MEG Devices

§ Other Monitoring Devices

By End User

· Hospitals

· Ambulatory Surgery Centers & Clinics

· Neurology Centres

· Diagnostic Centres

· Home Care Settings

Some of the key geographies mentioned in this report include:

· North America (U.S and Canada and rest of North America)

· Europe (Germany, France, Italy and Rest of Europe)

· Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)

· LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Recent Developments

· In February 2021, BioSerenity and Premier Inc. entered into an agreement where the former was to serve as Premier’s contracted provider and serve approximately 4,000 US hospitals and 175,000 other providers.

· In January 2021, Nihon Kohden launched disposable EEG electrodes to help prevent cross-contamination between patients and healthcare workers while maintaining high-quality EEG signals.

· In July 2020, Magstim acquired Philips’ subsidiary, EGI, adding high-density EEG solutions to its product portfolio. This acquisition helped the company close the loop for the development of a comprehensive system for non-invasive neuromodulation.

· In May 2020, Natus Medical announced a partnership with Holberg to develop and distribute the Autoscore algorithm. The algorithm helps automate electroencephalography (EEG) classifications and advance reporting efficiency.

Key Deliverables in the Study:

· Overall market landscape for the Global Epilepsy Monitoring Devices Market, along with the regional analysis and competitive analysis, based on the regional and global scales.

· Market definition and market dynamics, including drivers, restraints, challenges, threats, and potential growth opportunities.

· Factors responsible for changing the market landscape, soaring opportunities, and identification of leading competitors that will impact the growth of the market on a regional and global scale.

· Detailed analysis of the leading industry participants along with their company profiles, supply chain trends, technological advancements, inventions, and key developments.

· In-depth analysis of the macro- and micro factors that will have an impact on the growth of the market, on a regional and global scale.

· Detailed assessment of the financial information and the current strategies of the leading key players functioning in the market.

· An in-depth understanding and insights about the key industry players and the strategies adopted by them to sustain and grow in the Global Epilepsy Monitoring Devices Market.

Research Study Source:

https://www.marketsandmarkets.com/ResearchInsight/epilepsy-monitoring-devices-market.asp

https://www.marketsandmarkets.com/PressReleases/epilepsy-monitoring-devices.asp

https://www.prnewswire.com/news-releases/epilepsy-monitoring-devices-market-worth-615-million-by-2026--exclusive-report-by-marketsandmarkets-301398110.html

The market research report on the Global Patient Experience Technology Marketpresents an in-depth information about the various aspects of the market, on both global and regional scales, which provides a better understanding of the present market landscape. The growth of the Patient Experience Technology market has been driven by the soaring demand for Patient Experience Technology in the well-established and emerging regions, current technological advancements, and the growing infiltration of the end-use industries.

Browse 19 market data Tables and 22 Figures spread through 88 Pages and in-depth TOC on "Patient Experience Technology Market by Component (Technology (Patient Rounding, Patient experience survey), Consulting Services) & Facility Type (Acute Care, Post Acute Care, Non Acute Care (Physicians Office, Clinics)) - US Forecasts to 2026"

The patient experience technology market is projected to reach USD 299 million by 2026 from USD 179 million in 2021, at a CAGR of 10.7% during the forecast period. Growth in this market is driven by factors such as the favorable government regulations and initiatives to promote the adoption of HCIT solutions, the advantages of patient rounding solutions, and the growing number of collaborations and partnerships between stakeholders. However, factors such as the high investments for IT infrastructure and the shortage of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market to a certain extent during the forecast period.

Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72653597

The report presents some illustrations and presentations with regard to the market, which includes graphs, tables and pie charts, representing the percentage split of the strategies adopted by the key players in the global market. The product launches are regarded as one of the key strategies adopted by the leading market competitors in the Global Patient Experience Technology Market so as to present novel and innovative products in different business segments.

The prominent players operating in the US patient experience technology market are Sodexo (France), Press Ganey Associates (US), Vocera Communications (US), Huron Consulting Group (US), Aramark (US), CipherHealth (US), Accenture (US), Qualtrics (US), GetWell (US), and HybridChart (US).

The study categorizes the US patient experience technology market into the following segments and subsegments:

By Component

· Technology

o Patient Rounding

o Patient experience survey

o Consulting Services

By Facility Type

· Acute care facility

o Acute Hospitals

o Childrens Hospitals

o Academic medical center

o Military Treatment Facility

o Ambulatory Surgery Center

· Post Acte Care Facility

o Long term acute facility

o Skilled Nursing Facility

o Other

· Non Acute care Facility

o Physicians Office

o Clinics

Some of the key geographies mentioned in this report include:

· North America (U.S and Canada and rest of North America)

· Europe (Germany, France, Italy and Rest of Europe)

· Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)

· LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Recent Developments:

· In 2021, Press Ganey (US) partnered with The Beryl Institute (US), a global network of healthcare professionals and experienced champions. Through this partnership, Press Ganey will focus on advancing the healthcare experience movement.

· In 2021, Vocera (US) collaborated with Amazon (US) to build the Vocera Skill tool for Alexa. Vocera Skill will expand Vocera’s ecosystem to include hands-free and immersive voice experiences for patients and families.

· In 2021, SONIFI Health (US) and CipherHealth (US) entered into a strategic partnership to leverage the key capabilities of both solution providers and offer health systems a more holistic approach to patient communication and successful care planning.

Key Deliverables in the Study:

· Overall market landscape for the Global Patient Experience Technology Market, along with the regional analysis and competitive analysis, based on the regional and global scales.

· Market definition and market dynamics, including drivers, restraints, challenges, threats, and potential growth opportunities.

· Factors responsible for changing the market landscape, soaring opportunities, and identification of leading competitors that will impact the growth of the market on a regional and global scale.

· Detailed analysis of the leading industry participants along with their company profiles, supply chain trends, technological advancements, inventions, and key developments.

· In-depth analysis of the macro- and micro factors that will have an impact on the growth of the market, on a regional and global scale.

· Detailed assessment of the financial information and the current strategies of the leading key players functioning in the market.

· An in-depth understanding and insights about the key industry players and the strategies adopted by them to sustain and grow in the Global Patient Experience Technology Market.

Related Research Study Source:

https://www.prnewswire.com/news-releases/patient-experience-technology-market-worth-299-million-by-2026--exclusive-report-by-marketsandmarkets-301503106.html

https://www.marketsandmarkets.com/PressReleases/patient-experience-technology.asp

https://www.marketsandmarkets.com/ResearchInsight/patient-experience-technology-market.asp

Introduction to Home Healthcare

Home healthcare is a type of healthcare provided in a patient's home for the treatment of an illness or injury. It includes a variety of healthcare services, such as nursing care, physical therapy, occupational therapy, and other medical treatments. Home healthcare can be provided by a variety of providers, including a home health agency, a private nurse, or a family member. Home healthcare is a cost-effective way to receive care in the comfort of one's own home. Home healthcare can help improve quality of life, reduce hospitalizations and readmissions, and reduce the overall cost of healthcare.

The report "Home Healthcare Market Size, Growth by Product (Dialysis Equipment, IV Equipment, Ventilators, Coagulation Monitors, Peak Flow Meters), Service (Infusion Therapy, Skilled Nursing, Hospice), Indication (Cancer, Wound Care, Diabetes), and Region - Global Forecast to 2027 ", is projected to reach USD 340.2 billion by 2027, at a CAGR of 8.5%.

Benefits of Home Healthcare

· Increased Independence - Home healthcare allows individuals to remain in the comfort of their own home, increasing their independence and empowering them to take charge of their own health and well-being.

· Reduced Risk of Infection - One of the primary benefits of home healthcare is that it reduces the risk of infection. Home healthcare professionals are experienced in providing care in a safe and hygienic manner.

· Improved Quality of Care - Home healthcare also allows for more personalized care that is tailored to an individual’s specific needs.

· Cost Savings - Home healthcare is often less expensive than care provided in a hospital or other health care facility.

· Access to Specialized Care - Home healthcare can also provide access to specialized care that is not available in a hospital or other health care facility.

· Increased Comfort - Home healthcare allows individuals to receive care in the comfort of their own home, reducing the stress and anxiety associated with a hospital stay

How Home Healthcare Works

Home healthcare is a form of medical care provided in the home of the patient, rather than in a hospital or care facility. Home healthcare services can be provided by a variety of healthcare professionals, including nurses, physicians, physical therapists, occupational therapists, and social workers. Home healthcare services can be used to treat chronic conditions, manage post-hospitalization care, help with activities of daily living, and provide palliative and end-of-life care.

Home healthcare services typically involve a comprehensive assessment of the patient's medical needs, including their physical and mental health. During this assessment, the home healthcare provider will develop a care plan that outlines the services needed, the frequency of visits, and the duration of care. The care plan is tailored to the individual patient's needs and is regularly updated to reflect changes in the patient's condition.

Home healthcare services may include administering medications, providing medical treatments, monitoring vital signs, providing assistance with personal care and hygiene, and providing emotional support. Home healthcare providers will also provide education and support to family members and caregivers. Home healthcare services can range from short-term care to long-term care, depending on the individual's needs. Home healthcare is typically covered by Medicare, Medicaid, and private insurance.

Types of Home Healthcare Services

· Skilled Nursing Care: Skilled nursing care involves medical and nursing care provided by a registered nurse (RN) or a licensed practical nurse (LPN). It includes administering medication, wound care, IV therapy, and other medical treatments.

· Physical Therapy: Physical therapy helps patients improve strength, balance, and mobility. It includes exercises, stretches, and manual therapy techniques such as massage.

· Occupational Therapy: Occupational therapy helps patients perform everyday activities, such as self-care, dressing, and cooking.

· Speech Therapy: Speech therapy helps people improve their communication and swallowing skills.

· Mental Health Services: Mental health services include therapy, counseling, and support for people with mental health conditions.

· Social Services: Social services help patients access resources and services in their community, such as housing, transportation, and financial assistance.

· Home Health Aide Services: Home health aides provide assistance with activities of daily living, such as bathing, dressing, and meal preparation.

· Medical Equipment and Supplies: Home healthcare services may include providing medical equipment and supplies, such as wheelchairs, walkers, oxygen tanks, and catheters.

Common Conditions Treated with Home Healthcare

· Chronic Obstructive Pulmonary Disease (COPD)

· Congestive Heart Failure (CHF)

· Diabetes

· Alzheimer’s Disease

· Cancer

· Post-Stroke Care

· Orthopedic Injuries

· Osteoarthritis

· Multiple Sclerosis

· Parkinson’s Disease

Challenges of Home Healthcare

1. Limited access to medical supplies and equipment: Home health care providers often have limited access to medical supplies, equipment, and medications due to cost or availability.

2. Difficulty managing chronic conditions: Managing chronic conditions at home can be difficult for both the caregiver and the patient. It requires regular monitoring and adherence to a specific care plan.

3. Isolation: Home health care can lead to a feeling of isolation for both the patient and the caregiver. The patient may feel isolated from the outside world and the caregiver may feel isolated from the patient’s social circle.

4. Financial burden: Home health care services may be expensive and may not be covered by insurance.

5. Lack of support: Home health care providers often lack access to a larger support system, such as family members, friends, or other professionals. This can make it difficult to provide quality care.

Cost of Home Healthcare

The cost of home healthcare varies depending on the type of care that is required. Costs may range anywhere from $10 to $100 per hour for basic services such as companion care and light housekeeping, to $25 to $300 per hour for more advanced services such as medical care and nursing services. Some insurance plans may cover some or all of the costs of home healthcare.

Choosing a Home Healthcare Provider

When choosing a home healthcare provider, it is important to consider the level of care needed, the provider's qualifications, and their experience. The provider should be licensed, certified, and accredited. It is also important to make sure they have the necessary equipment and supplies to provide the best care possible. Additionally, it is important to ask about their rates and any payment options they offer. Finally, it is important to ask for references and to speak with them to ensure the provider is a good fit for the patient's needs.

Safety Considerations for Home Healthcare

1. Use proper body mechanics when providing care.

2. Wear gloves and other protective gear when necessary.

3. Perform regular inspections of the home’s environment to identify potential safety hazards.

4. Be aware of potential tripping and slipping hazards and take steps to reduce the risk.

5. Ensure that the patient’s home is free of any clutter and that items are not left on the floor or stairs.

6. Utilize appropriate assistive devices to facilitate safe movement and transfers.

7. Ensure that the patient’s home has adequate lighting for nighttime care.

8. Maintain adequate ventilation and temperature control in the patient’s home.

9. Ensure that all electrical outlets and appliances are in good working order and in accordance with safety standards.

10. Keep all medications and medical supplies in a secure and safe location.

Conclusion for Home Healthcare

Home healthcare is a valuable and efficient way to provide quality healthcare to those who may not otherwise have access to it. It allows patients to receive the same quality of care in their own home as they would in a hospital or doctor's office, while reducing costs and increasing convenience. Home healthcare provides personalized care that is tailored to the individual needs of each patient and can help improve quality of life by allowing them to remain in the comfort of their home. With the right home healthcare plan, patients can enjoy improved physical and mental health while remaining in the safety and comfort of their own home.

Related Content:

https://www.marketsandmarkets.com/Market-Reports/home-healthcare-equipment-market-696.html

https://www.marketsandmarkets.com/PressReleases/home-healthcare.asp

https://www.prnewswire.com/news-releases/home-healthcare-market-worth-340-2-billion-by-2027---exclusive-report-by-marketsandmarkets-301686703.html

Introduction to Companion Diagnostics Market

Companion diagnostics are tests that are used in combination with specific therapies to identify or predict the likelihood of a patient's response to a particular treatment. Companion diagnostics are used to select the right treatment for the right patient, as well as to avoid toxicity or other side effects associated with a given therapy. Companion diagnostics provide tailored treatments and help to improve clinical outcomes, reduce healthcare costs, and reduce the risks of adverse events. Companion diagnostics provide actionable information about the individual patient that helps in the selection of the best possible treatment for the patient. They are used in the field of personalized medicine, which is an emerging field that utilizes diagnostics and treatments tailored to a patient's individual characteristics to improve their health outcomes. Currently, companion diagnostics are used in the field of oncology, but their use is expected to increase in other therapeutic areas in the near future. The global companion diagnostics market is expected to witness a significant growth in the coming years due to the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the increasing number of clinical trials for the development of companion diagnostics.

Overview of the Companion Diagnostics Market:

The global companion diagnostics market in terms of revenue was estimated to be worth $5.5 billion in 2021 and is poised to reach $9.9 billion by 2026, growing at a CAGR of 12.6% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

Companion diagnostics are medical tests used in conjunction with therapeutic drugs to guide personalized therapy decisions. These tests provide information about the patient's genetic makeup, disease progression, and drug response, which helps to determine the best course of treatment. The tests are used to diagnose and monitor disease progression, predict prognosis, and determine the most appropriate therapy. Companion diagnostics are used in cancer, infectious diseases, cardiovascular diseases, and other chronic diseases.

The increasing prevalence of cancer and other chronic diseases, the rising demand for personalized medicine, the growing awareness about personalized medicine, and the increasing number of research and development activities in the field of personalized medicine are some of the major factors driving the growth of the market. In addition, the increasing adoption of nucleic acid-based tests, the growing demand for precision medicine, and the increasing focus on the development of gene- and protein-based tests are some of the other factors driving the market growth.

Drivers of the Companion Diagnostics Market:

1. Technological Advancements: Technological advancements have resulted in the development of new and improved companion diagnostics tests. Companies are investing in the development of innovative technologies such as next-generation sequencing (NGS) and digital PCR that have allowed for the development of highly sensitive and reliable tests. These tests can detect the presence of a particular mutation in a sample with greater accuracy than ever before. This has enabled physicians to customize treatments and therapies for their patients, leading to better outcomes.

2. Growth of Personalized Medicine: The emergence of personalized medicine has further increased the demand for companion diagnostics. Personalized medicine is based on the concept of providing targeted treatments to individuals based on their unique genetic makeup. Companion diagnostics tests can be used to detect the presence of specific mutations that can help physicians identify the most suitable treatment for their patients.

3. Increasing Prevalence of Cancer: The prevalence of cancer is increasing globally, leading to an increased demand for diagnostic tests that can accurately identify the presence of cancer and aid in the selection of the most suitable treatment. Companion diagnostics tests can be used to detect the presence of specific mutations in a sample, enabling physicians to customize their treatments and therapies for their patients.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681

Challenges Faced by the Companion Diagnostics Market:

1. Regulatory Hurdles: The companion diagnostics market is subject to stringent regulations imposed by multiple regulatory agencies, such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional regulatory bodies. The approval process for companion diagnostics is complex, lengthy, and expensive, making it difficult for companies to develop, launch, and commercialize their products.

2. High Cost of Tests: The cost of companion diagnostics tests is often high, which can limit the accessibility of these tests. The cost of the test depends on the type of test, the complexity of the test, and the availability of technology and equipment.

3. Limited Accessibility: The availability of companion diagnostics is limited in certain regions due to the lack of infrastructure, technology, and expertise. In some cases, reimbursement policies are also a barrier to access. Furthermore, some countries lack the necessary regulatory and legal frameworks to support the development and commercialization of companion diagnostics.

Growth Opportunities for Companion Diagnostics:

Companion diagnostics is a rapidly evolving field that is expected to experience significant growth in the coming years. This is due to several factors, including growing awareness of the value of personalized medicine, increasing investment in research and development, and the increasing adoption of companion diagnostics.

1. Growing Awareness of the Value of Personalized Medicine: With the rise of personalized medicine, the use of companion diagnostics is becoming increasingly popular and widely accepted. This is because it enables physicians to provide more accurate and personalized treatments to patients based on their individual characteristics, such as genetic makeup, lifestyle, and environmental factors. In addition, the use of companion diagnostics helps to reduce costs associated with drug development and increases the efficiency of clinical trials. As more people become aware of the value of personalized medicine, the demand for companion diagnostics is expected to grow significantly.

2. Increasing Investment in Research and Development: The growth of the companion diagnostics market is also being driven by increased investment in research and development. As more companies invest in researching and developing new companion diagnostics, the technology is becoming more accessible and affordable. This, in turn, is allowing more people to benefit from the advantages of personalized medicine.

3. Increasing Adoption of Companion Diagnostics: Finally, the increasing adoption of companion diagnostics is driving the growth of the market. The increasing availability of companion diagnostics, coupled with the increasing awareness of the value of personalized medicine, is encouraging more people to use these tests. This is leading to an increase in demand and, consequently, growth in the market.

Key Players in the Companion Diagnostics Market: Roche, Abbott, and Agilent Technologies

Roche: Roche is a multinational healthcare company that is involved in the research, development, and production of a variety of drugs, diagnostics, and medical devices. It is one of the largest pharmaceutical companies in the world. Roche's products include companion diagnostics, such as the cobas EGFR Mutation Test, which is used to identify patients with non-small cell lung cancer who are eligible for treatment with the drug Tarceva.

Abbott: Abbott is an American healthcare company that manufactures and markets a wide range of medical devices, diagnostics, and nutrition products. Abbott's companion diagnostics portfolio includes its RealTime EGFR Mutation Test, which is used to detect EGFR mutations in patients with non-small cell lung cancer.

Agilent Technologies: Agilent Technologies is an American company that produces scientific instruments and software for the healthcare, chemical, and electronic industries. Agilent's companion diagnostics portfolio includes its Oncomine Focus Assay, which is used to detect genetic mutations in cancer patients.

Conclusion: Future of the Companion Diagnostics Market

The companion diagnostics market is expected to show significant growth in the years to come. With the rising demand for personalized medicine, the growing number of biopharmaceuticals in the development pipeline, and the increasing prevalence of cancer, the companion diagnostics market is expected to be driven by the need to identify and treat diseases more precisely. Furthermore, the booming healthcare IT industry and the growing emphasis on the use of companion diagnostics in research and drug development will further fuel the growth of this market. Consequently, it is expected that the companion diagnostics market will continue to experience steady growth in the near future.

Bariatric surgery devices are medical devices used to help with weight loss and treat obesity. These devices are used in conjunction with lifestyle changes and other treatments to help people achieve and maintain a healthy weight. The global bariatric surgery devices market is expected to grow at a CAGR of 5.4% from 2022 to 2027.

There are various types of bariatric surgery devices, including gastric bands, gastric bypasses, gastric sleeves, and gastric balloons. Each type of device has its own unique benefits and risks. For example, gastric bands are adjustable and reversible, while gastric bypasses are more permanent and require more extensive follow-up care. Gastric sleeves are also adjustable but are less invasive than other types of bariatric surgery devices.

Drivers of the bariatric surgery devices market include the increasing prevalence of obesity, a growing aging population, and technological advancements in bariatric surgery devices. Additionally, increasing awareness about the importance of healthy lifestyles and the availability of government subsidies for bariatric surgery are expected to further drive the market.

Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173150134

However, the high cost of bariatric surgery devices, the risk of complications, and limited insurance coverage are some of the factors that could restrain the growth of the market.

The bariatric surgery devices market is categorized based on device type, end user, and region. By device type, the market is segmented into gastric bands, gastric bypass, gastric sleeves, and gastric balloons. By end user, the market is divided into hospitals & clinics, ambulatory surgical centers, and other end users.

Geographically, the global bariatric surgery devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market owing to the rising prevalence of obesity, technological advancements, and increasing awareness about the importance of bariatric surgery.

The key players operating in the bariatric surgery devices market include:

Ethicon (Johnson & Johnson), Medtronic, Apollo Endosurgery, Inc., Intuitive Surgical, Inc., Aspire Bariatrics, Inc., Allurion Technologies Inc., Spatz FGIA, Inc., ReShape Lifesciences, Inc., and TransEnterix, Inc. These players are focusing on product innovation and strategic collaborations to gain a competitive edge in the market.

Request a Sample Copy: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173150134

This report categorizes the bariatric surgery devices market into the following segments and subsegments:

By Device Type

· Minimally Invasive Surgical Devices

o Stapling Devices

o Energy/Vessel-sealing Devices

o Suturing Devices

o Accessories

· Noninvasive Surgical Devices

By Procedure

· Sleeve Gastrectomy

· Gastric Bypass

· Revision Bariatric Surgery

· Noninvasive Bariatric Surgery

· Adjustable Gastric Banding

· Mini-gastric Bypass

· Biliopancreatic Diversion with Duodenal Switch (BPD/DS)

By Region

· North America

· Europe

· Asia Pacific

· Latin America

· Middle East & Africa

Recent Developments:

· In January 2022, Johnson & Johnson (US) signed a strategic partnership with Microsoft (US) to further enable its digital surgery solutions.

· In October 2021, Spatz Medical (US) received US FDA approval for its product, Spatz3 Gastric Balloon, the first adjustable gastric balloon, to aid in weight loss for adult patients struggling with obesity.

· In June 2021, ReShape Lifesciences Inc. (US) announced the completion of the merger with Obalon Therapeutics (US). In connection with the merger's closing, Obalon changed its name to ReShape Lifesciences Inc. The merger is expected to create opportunities for ReShape to expand its portfolio of FDA-approved weight loss solutions and reimbursed virtual care services.

· In March 2021, Johnson & Johnson (US) launched the ECHELON+ Stapler with GST Reloads, a powered surgical stapler designed to reduce complications in surgery through more uniform tissue compression and better staple formation.

· In March 2020, Intuitive Surgical, Inc. (US) received regulatory clearance in Japan to market its SynchroSeal instrument.

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road, Suite 430, Northbrook, IL 60062

USA: 1-888-600-6441 | sales@marketsandmarkets.com

Content Source:

https://www.marketsandmarkets.com/PressReleases/bariatric-surgery-device.asp

https://www.marketsandmarkets.com/ResearchInsight/bariatric-surgery-device-market.asp

https://www.prnewswire.com/news-releases/bariatric-surgery-devices-market-worth-2-4-billion-by-2027--exclusive-report-by-marketsandmarkets-301617701.html